An update on clinical care for pregnant women with acromegaly.
Philippe ChansonMagaly VialonPhilippe CaronPublished in: Expert review of endocrinology & metabolism (2019)
Based on the small number of reported cases, pregnancy is generally uneventful, except for a potential increased incidence of gestational hypertension and diabetes mellitus. Medical therapy of acromegaly (dopamine agonists, somatostatin analogs, growth hormone-receptor antagonists) is generally interrupted before or at diagnosis of pregnancy. In very rare patients with a pituitary adenoma, particularly a macroadenoma that has not been surgically treated before pregnancy, or if a surgical remnant persists, or when acromegaly is revealed during pregnancy, tumor volume may increase and cause symptoms through a mass effect. Close monitoring of clinical manifestations and imaging are necessary during pregnancy in these cases. In the rare cases of symptomatic tumor enlargement during pregnancy, medical treatment with dopamine agonists or eventually somatostatin analogs may be attempted before resorting to transsphenoidal surgery.
Keyphrases
- growth hormone
- pregnancy outcomes
- pregnant women
- healthcare
- preterm birth
- blood pressure
- uric acid
- minimally invasive
- molecular docking
- high resolution
- palliative care
- risk factors
- coronary artery bypass
- weight gain
- neuroendocrine tumors
- bone marrow
- type diabetes
- pain management
- metabolic syndrome
- skeletal muscle
- chronic pain
- risk assessment
- depressive symptoms
- newly diagnosed
- molecular dynamics simulations
- glycemic control
- replacement therapy
- insulin resistance
- photodynamic therapy
- percutaneous coronary intervention